In-Vivo CRISPR Lipid Nanoparticle Therapy Achieves 95% Attack Reduction for Hereditary Angioedema in NEJM Phase 2

The Three-Question Framework

What Happened?

Intellia Therapeutics and clinical investigators published complete Phase 2 clinical trial results in the New England Journal of Medicine (NEJM) for NTLA-2002, a single-dose systemic in vivo CRISPR/Cas9 gene editing medicine. Delivered via liver-targeted lipid nanoparticles (LNPs), the therapy achieved a 95% reduction in monthly swelling attacks in patients suffering from Hereditary Angioedema (HAE), with majority of participants becoming completely attack-free.

Why It Matters

While initial approved CRISPR therapies (such as Casgevy for sickle cell disease) require complex ex-vivo procedures where patient bone marrow cells are extracted, edited in an external cleanroom, and re-infused after toxic myeloablative chemotherapy, NTLA-2002 edits DNA directly inside the living human body via a routine two-hour IV drip. This establishes a scalable clinical paradigm for treating hundreds of genetic and metabolic liver disorders.

What Could Happen Next

Intellia initiated global Phase 3 pivotal trials following FDA Breakthrough Therapy designation, targeting formal biologics license application (BLA) submission for 2026–2027.

Executive Key Takeaways

95% reduction in swelling attacks: single 50mg infusion eliminates recurring life-threatening edema episodes.

Direct in-vivo editing: Cas9 mRNA and guide RNA delivered directly to human hepatocytes via lipid nanoparticles.

Targeted gene knockout: selectively inactivates KLKB1, reducing plasma kallikrein protein levels by over 86%.

Zero severe adverse events: no off-target genetic mutations detected in comprehensive genomic sequencing.

On August 18, 2026, the New England Journal of Medicine published clinical trial data demonstrating that in vivo CRISPR/Cas9 gene editing can achieve permanent therapeutic remission in human patients suffering from Hereditary Angioedema (HAE).

Hereditary Angioedema is a debilitating, potentially fatal genetic condition caused by uninhibited production of the peptide hormone bradykinin. Deficiencies in C1-esterase inhibitor allow the enzyme plasma kallikrein to over-cleave kininogen, triggering unpredictable, severe swelling attacks in the limbs, digestive tract, and airway. Conventional treatment requires lifelong, painful prophylactic injections every few weeks.

NTLA-2002 re-engineers treatment into a one-time definitive cure. The drug consists of lipid nanoparticles encapsulating Cas9 messenger RNA alongside a chemically modified single guide RNA (sgRNA) targeting the KLKB1 gene in the liver. When infused intravenously, the LNPs are taken up specifically by hepatocytes via the LDL receptor.

Inside the cell nucleus, the Cas9 enzyme creates a precise double-stranded break in the KLKB1 coding sequence. Natural non-homologous end joining (NHEJ) repair introduces insertion-deletion mutations that permanently silence the gene, halting kallikrein production at the source.

Trial data across 27 patients showed an 86% average decrease in circulating kallikrein and a 95% decrease in clinical attack frequency, with 75% of patients remaining entirely symptom-free after single-dose administration without ongoing medication.

The milestone confirms that systemic in-vivo CRISPR represents a viable commercial reality for human medicine.